ArticleObesity pillars2026
Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Central obesity, commonly assessed using waist circumference (WC), is strongly associated with cardiometabolic risk. While lifestyle interventions and glucagon-like peptide-1 receptor agonist-based therapies (GLP-1RA-based therapies) reduce body weight, their effects on WC and factors influencing response remain incompletely characterised. This systematic review and meta-analysis evaluated the effects of these interventions on WC in randomised controlled trials (RCTs). Methods: Following PRISMA 2020 guidelines, we searched PubMed for RCTs published between 2010 and 2025 that reported outcomes related to WC or visceral adipose tissue in adults. Eligible interventions included diet, exercise, diet plus exercise, and GLP-1RA-based therapies. Data from 27 intervention-comparator study arms (21 RCTs; n = 3196) were pooled using random-effects models to estimate between-group mean differences in WC change. Meta-regression explored associations between baseline characteristics and WC response. Publication bias was assessed using funnel plots and Egger's test. Results: Interventions were associated with significant reductions in WC (MD: -4.36 cm; 95% CI: -4.97 to -3.74; prediction interval: -6.98 to -1.73). Subgroup analyses demonstrated significant reductions for GLP-1RATs (MD -5.93 cm; 95% CI -7.88 to -3.98) and diet-alone interventions (MD -3.46 cm; 95% CI -5.91 to -1.00). Exercise-only and diet-plus-exercise interventions showed more variable effects, and subgroup differences were not statistically significant. Exploratory meta-regression suggested potential associations between baseline anthropometric measures, age, and WC reduction, although these findings should be interpreted cautiously. WC change was positively associated with visceral adipose tissue change at the study-arm level. Funnel plots suggested possible small-study effects (Egger's p = 0.0025). Conclusions: GLP-1RA-based therapies and dietary interventions were associated with reductions in WC in adults. WC may serve as a practical anthropometric marker of intervention response, although observed associations with visceral adipose tissue were derived from study-arm-level analyses. Further studies are needed to better define predictors of treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.